Where the stock stands
Biocon Ltd., a Healthcare-sector company, last traded at ₹395 in the latest price snapshot, up 1.28% on a previous close of ₹390, while the Nifty was up 0.14% on the day. The technical readings in the pack are not computed off that print: they carry a last date of 22 September and a close of ₹390, so every return and range figure below describes the stock as of that earlier close, one session behind the live price.
On that basis the stock sat 12.78% below its 52-week high of ₹447.15 and 15.71% above its 52-week low of ₹337.05, which places it in the lower-middle of its yearly range. Returns are mixed across horizons: up 2.09% over one week, down 4.73% over one month, down 6.28% over three months and up 5.63% over one year. On valuation the pack shows a price-to-earnings multiple of 116.52 on earnings per share of 3.39, a price-to-book of 1.88 and a dividend yield of 0.13%.
What the smart-money flow shows
The only named institutional activity in the pack falls on a single date, 14 July 2026. On the sell side, MYLAN INC. appears as the seller of a ₹1839.34 crore stake. That row is listed twice with an identical value, which is how the same trade shows up when it is reported as both a bulk and a block deal, so it should be read as one sale, not two. On the buy side, five mutual funds took stock the same day: ICICI Prudential Mutual Fund for ₹737.5 crore (also listed twice with the same value, again best treated as one trade), HDFC Mutual Fund and Kotak Mahindra Mutual Fund for ₹233.16 crore each, SBI Mutual Fund for ₹75 crore and Aditya Birla Sunlife Mutual Fund for ₹50 crore.
The shape is a large holder exiting in one print with domestic funds on the other side, a stake changing hands rather than a pattern of steady accumulation. The named fund purchases do not add up to the full size of the sale, so the pack does not identify every buyer. Separately, headlines dated 14 and 15 September refer to a stake sale in a Rs 635-cr block deal; no September deal appears in the institutional record, so the two sources disagree and the counterparties for that later trade are not in the data. The pack contains no F&O positioning, no institutional buying or selling streaks and no insider or promoter filings, so none of those can be assessed here.
The technical picture
As of the 22 September close, the stock was trading below both its 50-day and 200-day simple moving averages, the short- and long-run trend lines traders use as reference. Neither a golden cross nor a death cross (the 50-day line crossing above or below the 200-day line) is flagged. The 14-day RSI, a momentum gauge running from 0 to 100, stood at 42.7, below the midpoint but well clear of the oversold zone. Relative volume was 0.89, meaning trading activity was slightly under its usual level rather than showing any unusual surge.
Catalysts and what to watch
The most repeated item is an exchange filing, logged on 21, 22 and 23 September, relaying a company press release that says its pertuzumab product became the first biosimilar to secure an EMA CHMP approval recommendation under a new tailored clinical approach. A news headline dated 12 September reports a USFDA approval for liraglutide. According to Business Standard, the stock gained for a third straight session, and a Simply Wall St. headline lists it among pharma exporters facing fresh US tariff pressure. These are reports, and the pack offers no measured price reaction to any of them.
What the data establishes is a stock below its main moving averages, one session of technical lag against the live price, and a July stake transfer from MYLAN INC. to a group of mutual funds. It does not establish who stood behind the September block deal, any derivatives or insider positioning, or a single driver for the recent moves.